Drug profile · INN
fidanacogene elaparvovec
BEQVEZ (PREVIOUSLY DURVEQTIX)
fidanacogene elaparvovec (BEQVEZ (PREVIOUSLY DURVEQTIX)) is a coagulation factor ix exogenous gene.
EMA: withdrawn
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — fidanacogene elaparvovec
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
fidanacogene elaparvovec (BEQVEZ (PREVIOUSLY DURVEQTIX)) is a coagulation factor ix exogenous gene.
Key facts
INN fidanacogene elaparvovec
Brand BEQVEZ (PREVIOUSLY DURVEQTIX)
Mechanism Coagulation factor IX exogenous gene
Target Coagulation factor IX
Mechanism of action
Coagulation factor IX exogenous gene
Primary target: Coagulation factor IX
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fidanacogene elaparvovec?
fidanacogene elaparvovec (BEQVEZ (PREVIOUSLY DURVEQTIX)) is a coagulation factor ix exogenous gene.
What is the brand name for fidanacogene elaparvovec?
BEQVEZ (PREVIOUSLY DURVEQTIX) is a marketed brand name for fidanacogene elaparvovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.